NCT01211275 (N08CPA) is a Phase 1, PHASE2 clinical trial of axitinib in Malignant Pleural Mesothelioma, sponsored by The Netherlands Cancer Institute.

Who is sponsoring NCT01211275?

NCT01211275 is sponsored by The Netherlands Cancer Institute.

What drugs are being tested in NCT01211275?

Interventions in NCT01211275: axitinib, chemotherapy.

What condition does NCT01211275 study?

NCT01211275 studies Malignant Pleural Mesothelioma.

Is NCT01211275 still recruiting?

NCT01211275 is currently completed. Last updated 28 February 2017.

Last reviewed 2017-02-28 · How we verify

NCT01211275: N08CPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma

Completed Phase 1, PHASE2 Last updated 28 February 2017

What this trial tests

Phase 1, PHASE2 trial testing axitinib in Malignant Pleural Mesothelioma in 32 participants. Completed in 6 May 2013.

Timeline

22 May 2009

Primary endpoint
13 November 2012

6 May 2013

Quick facts

Lead sponsor	The Netherlands Cancer Institute
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	22 May 2009
Primary completion	13 November 2012
Estimated completion	6 May 2013
Sites	1 location across Netherlands

Drugs / interventions tested

axitinib — full drug profile →
chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Malignant Pleural Mesothelioma — all drugs for Malignant Pleural Mesothelioma →

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, any sex, with Malignant Pleural Mesothelioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients with mesothelioma

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
Mutti L, Peikert T, Robinson BWS, Scherpereel A, et al · · 2018 · cited 85× · PMID 29966799 · DOI 10.1016/j.jtho.2018.06.011
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.
Nicolini F, Bocchini M, Bronte G, Delmonte A, et al · · 2019 · cited 68× · PMID 32039010 · DOI 10.3389/fonc.2019.01519
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.
Kotova S, Wong RM, Cameron RB. · · 2015 · cited 25× · PMID 25670913 · DOI 10.2147/cmar.s72814
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.
Nabavi N, Bennewith KL, Churg A, Wang Y, et al · · 2016 · cited 17× · PMID 28191281 · DOI 10.18632/genesandcancer.124

Verify or expand the search:

Other trials of axitinib

Trials testing the same drug.

NCT05949632 — A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors · Phase 1, PHASE2 · terminated
NCT05256472 — A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma · Phase 2 · active not recruiting
NCT05650164 — Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Stu · completed
NCT05097599 — StrataPATH™ (Precision Indications for Approved Therapies) · Phase 2 · terminated
NCT05012865 — Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospec · completed

Other recruiting trials for Malignant Pleural Mesothelioma

Currently open trials in the same condition.

NCT05655078 — Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma · NA · recruiting
NCT06318286 — Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma · Phase 2 · recruiting
NCT04400539 — The IMmunotherapy Pleural 5-ALA PDT · Phase 2 · recruiting

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01211275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
Last refreshed: 28 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01211275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing